Carbapenemases in New York City: the continued decline of KPC-producing Klebsiella pneumoniae, but a new threat emerges.

Research paper by Alejandro A Iregui, Karen K Ha, Katharine K Meleney, David D Landman, John J Quale

Indexed on: 15 Aug '18Published on: 15 Aug '18Published in: The Journal of antimicrobial chemotherapy


Carbapenemase-producing Enterobacteriaceae are important nosocomial pathogens in many medical centres. Surveillance is needed to track trends and detect emergence of new carbapenemases. Single-patient isolates of Enterobacteriaceae were gathered from seven medical centres in New York City over a 3 month period in 2017. Susceptibility testing was performed and isolates were screened for selected carbapenemases. Additional isolates referred to our laboratory in 2018 were also tested. KPC was found in 3/1911 (0.16%) isolates of Escherichia coli, 22/533 (4.1%) isolates of Klebsiella pneumoniae and 3/175 (1.7%) isolates of Enterobacter spp. Compared with prior surveillance studies performed over the past decade, there has been a persistent decline in the number of KPC-possessing K. pneumoniae. However, in 2018 two patients from the same skilled nursing facility admitted to two separate hospitals were found to harbour Enterobacteriaceae with NDM-5 and CTX-M-15. Since the height of the outbreak in 2006, there has been a decline in the number of KPC-possessing Enterobacteriaceae in New York City acute care medical centres. However continued vigilance is needed to detect the emergence of other carbapenemases.